Health Condition 1: G31- Other degenerative diseases of nervous system, not elsewhere classified Health Condition 2: null- Zuâ??f al-DimÄ?gh (Cerebro-asthenia)
Conditions
Interventions
Intervention1: Khamira Gawzaban Sada: 10 grams orally once daily to be taken with water before breakfast for six weeks
Control Intervention1: nil: nil
Sponsors
Central Council for Research in Unani Medicine
Eligibility
Inclusion criteria
Inclusion criteria: The patients fulfilling the following criteria will be included in this study: 1. Patients of any sex in the age group 19-70 years 2. Patients of Zuâ??f al-DimÄ?gh (Cerebro-asthenia) having: ï?§ Subjective complaints of cognitive impairment ï?§ MMSE score of 10-23 representing mild to moderate cognitive impairment
Exclusion criteria
Exclusion criteria: 1. Clinical presentation and/or history of any significant organic neurological diseases including space occupying lesions, stroke, head injury, seizure, and mental retardation 2. Patients with impairment of speech, hearing and vision, which can impede the interview for MMSE and QOL assessment 3. Known cases of hypothyroidism or hyperthyroidism 4. Vitamin B12 deficiency 5. Patients on Psychotropic Drugs 6. Clinical presentation and/or history of a chronic disease that requires long-term treatment, e.g., DM, tuberculosis, HIV infection, syphilis, CVD, pulmonary disease, CKD, chronic liver disease, or any other serious and/or unstable medical condition that, in the opinion of the investigator, could expose the patients to undue risk of a significant adverse event or interfere with assessment of safety or efficacy during the course of the trial 7. Pregnant and lactating women 8. H/o Addiction (alcohol, drugs) 9. H/o Hypersensitivity to the study drug or any of its ingredients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in signs and symptoms of Zuâ??f al-DimÄ?gh (Cerebro-asthenia) Timepoint: 6 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Haematological and biochemical assessment for safety assessmentTimepoint: at baseline and at the end of treatment | — |
Countries
India
Contacts
Public ContactDr Pradeep Kumar
Central Council for Research in Unani Medicine
Outcome results
None listed